Evidence map›Paper›PMID 19895218›Full record

ReviewFuture microbiology2009

The vitamin D-antimicrobial peptide pathway and its role in protection against infection.

Adrian F Gombart

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05630339 (Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial), which is not on this map. Cited by 220 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
220citing papers in PubMed, 8 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05630339 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2022 to 2023Enrolled150ConditionsPost-COVID-19 Syndrome, Long COVID, Vitamin D Deficiency, Magnesium DeficiencyArmsMagnesium chloride, Vitamin D, Inert placebo
3 · Its place in the literature

Who cites it

220 citing papers in PubMed, 8 syntheses or guidelines pooled it, 438 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Vitamin DFrontiers in oral health · 2026
    Trial
  10. Trial
  11. Trial
  12. Impact of high-dose vitamin DNutrition (Burbank, Los Angeles County, Calif.) · 2017
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Further Evaluation of 1,25(OH)Animals : an open access journal from MDPI · 2026
    Article
  18. Review
  19. Article
  20. Review

160 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Adrian F GombartLinus Pauling Institute, Department of Biochemisty & Biophysics, Oregon State University, Corvallis, 97331-7305, USA. adrian.gombart@oregonstate.edu
Oregon State University · US

Funding

Regulating Cathelicidin Expression for Disease TherapyR01AI065604 · NIAID · OREGON STATE UNIVERSITY · PI GOMBART, ADRIAN FRIEDRICH · 2007 to 2011
$2.1M
NIAID NIH HHS 5R01AI065604-04NIAID NIH HHS R01 AI065604
6 · The paper itself

Abstract

Vitamin D deficiency has been correlated with increased rates of infection. Since the early 19th century, both environmental (i.e., sunlight) and dietary sources (cod liver) of vitamin D have been identified as treatments for TB. The recent discovery that vitamin D induces antimicrobial peptide gene expression explains, in part, the 'antibiotic' effect of vitamin D and has greatly renewed interest in the ability of vitamin D to improve immune function. Subsequent work indicates that this regulation is biologically important for the response of the innate immune system to wounds and infection and that deficiency may lead to suboptimal responses toward bacterial and viral infections. The regulation of the cathelicidin antimicrobial peptide gene is a human/primate-specific adaptation and is not conserved in other mammals. The capacity of the vitamin D receptor to act as a high-affinity receptor for vitamin D and a low-affinity receptor for secondary bile acids and potentially other novel nutritional compounds suggests that the evolutionary selection to place the cathelicidin gene under control of the vitamin D receptor allows for its regulation under both endocrine and xenobiotic response systems. Future studies in both humans and humanized mouse models will elucidate the importance of this regulation and lead to the development of potential therapeutic applications.

Indexed as

Metabolic Networks and PathwaysAnimalsAntimicrobial Cationic PeptidesBacterial InfectionsCathelicidinsGene Expression RegulationHumansImmunity, InnateReceptors, CalcitriolVitamin DVitamin D DeficiencyVitaminsAntimicrobial Cationic PeptidesCathelicidinsReceptors, CalcitriolVitamin DVitamins

Identifiers

PMID19895218
PMCPMC2821804
OpenAlexW2107021471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.